The risks associated with prenatal antidepressant exposure: time for a precision medicine approach

References

• Bjorn AM, Norgaard M, Hundborg HH, et al. Use of prescribed drugs among primiparous women: an 11-year population-based study in Denmark. Clinical Epidemiology. 2011;3:149–156.
   PubMedGoogle Scholar
• Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011;205:51 e1–8.
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Palmsten K, Avorn J, et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med. 2014 Jun 19;370:2397–2407.
   PubMed Web of Science ®Google Scholar
• Jimenez-Solem E, Andersen JT, Petersen M, et al. Prevalence of antidepressant use during pregnancy in Denmark, a Nation-Wide Cohort Study. PLoS One. 2013;8:e63034.
   PubMed Web of Science ®Google Scholar
• Svensson E, Ehrenstein V, Norgaard M, et al. Estimating the proportion of all observed birth defects occurring in pregnancies terminated by a second-trimester abortion. Epidemiology. 2014;25:866–871.
   PubMed Web of Science ®Google Scholar
• Pedersen LH, Petersen OB, Norgaard M, et al. Linkage between the Danish National Health Service Prescription Database, the Danish Fetal Medicine Database, and other Danish registries as a tool for the study of drug safety in pregnancy. Clinical Epidemiology. 2016;8:91–95.
   PubMed Web of Science ®Google Scholar
• Jameson JL, Longo DL. Precision medicine–personalized, problematic, and promising. N Engl J Med. 2015 Jun 4;372:2229–2234.
   PubMed Web of Science ®Google Scholar
• Dance A Medical histories. Nature. 2016 Sep 08 print;537:S52–S53.
   PubMedGoogle Scholar
• Daud AN, Bergman JE, Bakker MK, et al. Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins. Pharmacogenomics. 2014;15:1029–1041.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003 Jan 21;55:3–29.
   PubMed Web of Science ®Google Scholar
• Ewing G, Tatarchuk Y, Appleby D, et al. Placental transfer of antidepressant medications: implications for postnatal adaptation syndrome. Clin Pharmacokinet. 2015;54:359–370.
   PubMed Web of Science ®Google Scholar
• Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological epidemiology. Int J Epidemiol. 2017 Jan 20:dyw314.
   PubMed Web of Science ®Google Scholar
• Hemels ME, Einarson A, Koren G, et al. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. AnnPharmacother. 2005;39:803–809.
   Web of Science ®Google Scholar
• Broy P, Berard A. Gestational exposure to antidepressants and the risk of spontaneous abortion: a review. Curr Drug Deliv. 2010 Jan;7:76–92.
   PubMedGoogle Scholar
• Kjaersgaard MIS, Parner ET, Vestergaard M, et al. Prenatal antidepressant exposure and risk of spontaneous abortion – a population-based study. PLoS One. 2013;8:e72095.
   PubMed Web of Science ®Google Scholar
• Andersen JT, Andersen NL, Horwitz H, et al. Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage. Obstet Gynecol. 2014;124:655–661.
   PubMed Web of Science ®Google Scholar
• Grzeskowiak LE, Gilbert AL, Morrison JL. Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy. Eur J Clin Pharmacol. 2012 May;68(5):459-467.
   Google Scholar
• Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3 ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2008.
   Google Scholar
• Wilcox AJ, Baird DD, Weinberg CR. Time of implantation of the conceptus and loss of pregnancy. N Engl J Med. 1999;340:1796–1799.
   PubMed Web of Science ®Google Scholar
• Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013;74:e293–e308.
   PubMed Web of Science ®Google Scholar
• Furu K, Kieler H, Haglund B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. Bmj. 2015;350:h1798.
   PubMed Web of Science ®Google Scholar
• Jimenez-Solem E, Andersen JT, Petersen M, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open. 2012;2:e001148.
   Web of Science ®Google Scholar
• Malm H, Artama M, Gissler M, et al. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstetrics Gynecol. 2011;118:111–120.
   PubMed Web of Science ®Google Scholar
• Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. Nenglj Med. 2007;356:2675–2683.
   PubMed Web of Science ®Google Scholar
• Reefhuis J, Devine O, Friedman JM, et al. Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports. Bmj. 2015;351:h3190.
   PubMed Web of Science ®Google Scholar
• Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstetrics Gynecol. 2005;106:1289–1296.
   PubMed Web of Science ®Google Scholar
• Berard A, Zhao JP, Sheehy O. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open. 2017 Jan 12;7:e013372.
   PubMed Web of Science ®Google Scholar
• Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. Bmj. 2009;339:b3569.
   PubMed Web of Science ®Google Scholar
• Daud AN, Bergman JE, Kerstjens-Frederikse WS, et al. The risk of congenital heart anomalies following prenatal exposure to serotonin reuptake inhibitors-is pharmacogenetics the key? Int J Mol Sci. 2016;17:1333.
   PubMed Web of Science ®Google Scholar
• Nembhard WN, Tang X, Hu Z, et al. Maternal and infant genetic variants, maternal periconceptional use of selective serotonin reuptake inhibitors, and risk of congenital heart defects in offspring: population based study. Bmj. 2017 Mar 06;356:j832.
   PubMed Web of Science ®Google Scholar
• de Vera MA, Berard A. Antidepressant use during pregnancy and the risk of pregnancy-induced hypertension. Br J Clin Pharmacol. 2012 Aug;74:362–369.
   PubMed Web of Science ®Google Scholar
• Palmsten K, Setoguchi S, Margulis AV, et al. Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants? Am J Epidemiol. 2012 May 15;175:988–997.
   PubMed Web of Science ®Google Scholar
• Toh S, Mitchell AA, Louik C, et al. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry. 2009;166:320–328.
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Sanghani RS, Avorn J, et al. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS One. 2014;9:e92778.
   PubMed Web of Science ®Google Scholar
• Grzeskowiak LE, McBain R, Dekker GA, et al. Antidepressant use in late gestation and risk of postpartum haemorrhage: a retrospective cohort study. Bjog. 2016;123:1929–1936.
   PubMed Web of Science ®Google Scholar
• Grzeskowiak LE, Pedersen LH, Morrison JL. Antidepressant use and gestational hypertension: does evidence support causality? Br J Clin Pharmacol. 2013 May;75(5):1373–1374.
   Google Scholar
• Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005;293:2372–2383.
   PubMed Web of Science ®Google Scholar
• Sanz EJ, Las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:482–487.
   PubMed Web of Science ®Google Scholar
• Bromiker R, Kaplan M. Apparent intrauterine fetal withdrawal from clomipramine hydrochloride. JAMA. 1994 Dec 14;272:1722–1723.
   PubMed Web of Science ®Google Scholar
• Gillman PK Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007 April 30 01/23/received, 02/26/revised, 02/26/accepted;151:737–748.
   PubMed Web of Science ®Google Scholar
• Chambers CD, Hernandez-Diaz S, van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579–587.
   PubMed Web of Science ®Google Scholar
• Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2008 Aug;17:801–806.
   PubMed Web of Science ®Google Scholar
• Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. Bmj. 2012;344:d8012–d12.
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Bateman BT, Palmsten K, et al. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015 Jun 02;313:2142–2151.
   PubMed Web of Science ®Google Scholar
• Brown AS, Gyllenberg D, Malm H, et al. Association of selective serotonin reuptake inhibitor exposure during pregnancy with speech, scholastic, and motor disorders in offspring. JAMA Psychiatry. 2016 Nov 01;73:1163–1170.
   PubMed Web of Science ®Google Scholar
• Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics. 2010;125:e600–e608.
   PubMed Web of Science ®Google Scholar
• Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. JPediatr. 2003;142:402–408.
   PubMed Web of Science ®Google Scholar
• Clements CC, Castro VM, Blumenthal SR, et al. Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system. Mol Psychiatry. 2015 Jun;20(6):727-734.
   Google Scholar
• Malm H, Brown AS, Gissler M, et al. Gestational exposure to selective serotonin reuptake inhibitors and offspring psychiatric disorders: a national register-based study. J Am Acad Child Adolesc Psychiatry. 2016;55:359–366.
   PubMed Web of Science ®Google Scholar
• Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry. 2011;68:1104–1112.
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Gingrich JA, Ansorge MS. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther. 2009 Dec;86:672–677.
   PubMed Web of Science ®Google Scholar
• Ansorge MS, Zhou M, Lira A, et al. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science. 2004;306:879–881.
   PubMed Web of Science ®Google Scholar
• Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. NEnglJMed. 1997;336:258–262.
   PubMed Web of Science ®Google Scholar
• Grzeskowiak LE, Morrison JL, Henriksen TB, et al. Prenatal antidepressant exposure and child behavioural outcomes at 7 years of age: a study within the Danish National Birth Cohort. Bjog. 2016;123:1919–1928.
   PubMed Web of Science ®Google Scholar
• Sorensen MJ, Gronborg TK, Christensen J, et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clinical Epidemiology. 2013;5:449–459.
   PubMedGoogle Scholar
• Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med. 2013 Dec 19;369:2406–2415.
   PubMed Web of Science ®Google Scholar
• Mao Y, Pedersen LH, Christensen J, et al. Prenatal exposure to antidepressants and risk of epilepsy in childhood. Pharmacoepidemiol Drug Saf. 2016 Aug 1;25:1320–1330.
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatrics Adolesc Med. 2007;161:22–29.
   PubMed Web of Science ®Google Scholar
• Misri S, Reebye P, Kendrick K, et al. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am J Psychiatry. 2006;163:1026–1032.
   PubMed Web of Science ®Google Scholar
• Pedersen L. Prenatal antidepressant exposure and childhood autism spectrum disorders: cause for concern?. Paediatr Drugs. 2015 Dec;17(6):443-448.
   Google Scholar
• Grzeskowiak LE, Gilbert AL, Sorensen TI, et al. Prenatal exposure to selective serotonin reuptake inhibitors and childhood overweight at 7 years of age. Ann Epidemiol. 2013;23:681–687.
   PubMed Web of Science ®Google Scholar
• Devlin AM, Brain U, Austin J, et al. Prenatal exposure to maternal depressed mood and the MTHFRC677T variant affect SLC6A4 methylation in infants at birth. PLoS One. 2010;5:e12201.
   PubMed Web of Science ®Google Scholar
• Viuff AC, Pedersen LH, Kyng K, et al. Antidepressant medication during pregnancy and epigenetic changes in umbilical cord blood: a systematic review. Clinical Epigenetics. 2016;8:94.
   PubMed Web of Science ®Google Scholar
• Drew L Pharmacogenetics: the right drug for you. Nature. 2016 Sep 08 print;537:S60–S62.
   PubMed Web of Science ®Google Scholar
• Iqbal M, Audette MC, Petropoulos S, et al. Placental drug transporters and their role in fetal protection. Placenta. 2012;33:137–142.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98:127–134.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Swen JJ, Thorn CF, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93:402–408.
   PubMed Web of Science ®Google Scholar
• Roca A, Garcia-Esteve L, Imaz ML, et al. Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose. J Affect Disord. 2011 Sep 2;135:208–215.
   PubMed Web of Science ®Google Scholar
• Bonnin A, Goeden N, Chen K, et al. A transient placental source of serotonin for the fetal forebrain. Nature. 2011;472:347–350.
   PubMed Web of Science ®Google Scholar
• Velasquez JC, Goeden N, Bonnin A. Placental serotonin: implications for the developmental effects of SSRIs and maternal depression. Front Cell Neurosci. 2013;7:47.
   PubMed Web of Science ®Google Scholar
• Kolvraa S, Singh R, Normand EA, et al. Genome-wide copy number analysis on DNA from fetal cells isolated from the blood of pregnant women. Prenat Diagn. 2016;36:1127–1134.
   PubMed Web of Science ®Google Scholar
• Lash TL, Fox MP, Fink AK. Applying quantitative bias analysis to epidemiologic data. New York, USA: Springer; 2009.
   Google Scholar
• Muller CL, Anacker AM, Rogers TD, et al. Impact of maternal serotonin transporter genotype on placental serotonin, fetal forebrain serotonin, and neurodevelopment. Neuropsychopharmacology. 2017 Jan;42(2):427-436.
   Web of Science ®Google Scholar
• Chen Y, Pedersen LH, Chu WW, et al. Drug exposure side effects from mining pregnancy data. SIGKDD Explor. 2007;9:22–29.
   Google Scholar
• Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011 Aug 15;157C:175–182.
   PubMed Web of Science ®Google Scholar